Michael H. Tardugno, Executive Chairman of the Board at Imunon, Inc., filed a Form 4 on November 10, 2026, disclosing the acquisition of 9,969 shares of common stock on November 6, 2026, granted in lieu of cash for base salary.

Key Highlights

  • Reporting person: Michael H. Tardugno, Executive Chairman of the Board and Director at Imunon, Inc. (NASDAQ:IMNN)
  • Transaction date: November 6, 2026, with the form filed November 10, 2026
  • Shares acquired: 9,969 shares of common stock, coded as an acquisition (A)
  • Transaction price: $0.845 per share
  • Nature of grant: According to the filing, the stock was "granted in lieu of cash for base salary"
  • Direct beneficial ownership following transaction: 128,511 shares of common stock held directly
  • Indirect ownership: An additional 4,622 shares held indirectly through an IRA

Imunon Executive Chairman Receives Salary-in-Stock Grant in November 2026

According to the Form 4 filing, Tardugno received 9,969 shares of Imunon, Inc. common stock on November 6, 2026, at a price of $0.845 per share. The filing states that these shares were "stock granted in lieu of cash for base salary," meaning the award represents compensation rather than an open-market purchase. The transaction is coded as an acquisition (A) under Table I - Non-Derivative Securities.

Following the reported transaction, the filing discloses that Tardugno directly beneficially owns 128,511 shares of Imunon common stock. In addition, the filing reports 4,622 shares held indirectly through an IRA. No derivative securities transactions were reported in Table II of this filing. The form was signed by Jeffrey W. Church as Attorney in Fact for Michael H. Tardugno and filed on November 10, 2026.

Tardugno is identified in the filing as both a Director and an Officer, with the title of Executive Chairman of the Board. His address of record is listed as c/o Imunon, Inc., 997 Lenox Drive, Suite 100, Lawrenceville, New Jersey 08648. No amendment date is indicated, meaning this is an original filing rather than a revision of a prior submission.

What Was Disclosed

Imunon's Executive Chairman Michael H. Tardugno disclosed the acquisition of 9,969 shares of common stock at $0.845 per share on November 6, 2026, as stock granted in lieu of cash for base salary, bringing his direct holdings to 128,511 shares.